Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391920 · ClinicalTrials.gov registry record
Registry of CytoSorb Therapy in COVID-19 ICU Patients
A clinical trial, sponsored by CytoSorbents.
- Completed
- Registry status
- 138
- Enrollment target
NCT04391920: Completed study, sponsored by CytoSorbents.
NCT04391920 is a clinical trial that has completed, run by CytoSorbents. The registered enrollment target is 138 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04391920 has completed, sponsored by CytoSorbents.
- COMPLETED
- Registry status
- 138 participants
- Enrollment target
Study Summary
The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.
Interventions
- DEVICE CytoSorb 300 mL device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2022-01-20 |
What the finished NCT04391920 record still lists
NCT04391920 is an observational study that tracks outcomes without assigning an intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which CytoSorb 300 mL device is the first listed.
NCT04391920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04391920 about?
NCT04391920 is a clinical study titled "Registry of CytoSorb Therapy in COVID-19 ICU Patients". The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption prov...
What is the current status of trial NCT04391920?
This trial is currently completed. The enrollment target is 138 participants. The study started on 2020-08-28. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT04391920?
The interventions under investigation include: CytoSorb 300 mL device (DEVICE).
Who is sponsoring clinical trial NCT04391920?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI